- Open Access
Correction to: Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy
BMC Cancervolume 19, Article number: 438 (2019)
The original article was published in BMC Cancer 2018 18:1203
Correction to: Knoerl et al. BMC Cancer (2018) 18:1203
Following publication of the original article , the authors reported that the chemotherapy dosages in the footnote of Table 1 should be in mg, and not mg/m2.
The footnote for Table 1 should read as follows:
This table describes the demographic characteristics of the patients at baseline.
aTo compare distribution of cancer diagnosis for intervention versus control, the diagnoses with < 10 observations are grouped together into another category (i.e., esophageal, testicular, gastrointestinal, miscellaneous, sarcoma, bladder, gastric, pancreatic and unknown primary).
bFor participants receiving multiple neurotoxic chemotherapy agents, dose category was determined based on the highest dose of one of the specific agents they were receiving.
cPaclitaxel < 700 mg; Oxaliplatin < 800 mg; Docetaxel < 300 mg; Cisplatin < 300 mg.
dPaclitaxel 700–1400 mg; Oxaliplatin 800–1000 mg; Docetaxel 300–600 mg; Cisplatin 300–600 mg.
ePaclitaxel > 1400 mg; Oxaliplatin > 1000 mg; Docetaxel > 600 mg; Cisplatin > 600 mg.
fNeurotoxic chemotherapy dose reduction due to other symptom-related causes included fatigue, pain, skin changes, bowel problems, or breathing problems.
Knoerl et al. BMC Cancer (2018) 18:1203. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy. https://doi.org/10.1186/s12885-018-5093-z.